CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

{
  "signal_id": "3218701b-cbf7-9a11-4446-f2f56582ea4b",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-18T10:45:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/18/3364612/0/en/chmp-recommends-eu-approval-of-roche-s-ocrevus-for-children-and-adolescents-with-relapsing-multiple-sclerosis.html",
    "title": "CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis",
    "excerpt": "Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ocrevus® (ocrelizumab) intravenous (IV) infusion for the treatment of paediatric patients aged 10 years and older with relapsing forms of multiple sclerosis (RMS). The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future.",
    "product": "Ocrevus",
    "summary": "Roche's Ocrevus intravenous infusion has been recommended for approval by the European Medicines Agency's CHMP for treating children and adolescents with relapsing multiple sclerosis, with a final decision from the European Commission expected soon.",
    "location": "Basel, Switzerland",
    "planning": true,
    "confidence": 0.9,
    "product_data": {
      "name": "Ocrevus",
      "full_text": "Ocrevus® (ocrelizumab) intravenous (IV) infusion",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-18T10:45:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ocrevus® (ocrelizumab) intravenous (IV) infusion for the treatment of paediatric patients aged 10 years and older with relapsing forms of multiple sclerosis (RMS)."
  }
}

curl https://signals.autobound.ai/v1/signals/3218701b-cbf7-9a11-4446-f2f56582ea4b \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"roche.com","limit":20}'